Latest news

7.8.2026

Cyllene Therapeutics Raises €33 Million Series C

Cyllene Therapeutics, formerly known as EG 427, raised a €33 million Series C financing round co-led by GordonMD and Merck Ventures with participation from SCI Ventures
8/7/26
Cyllene Therapeutics Raises €33 Million Series C
8/7/26
Craig Hospital joins SCI Ventures as Alliance Partner
8/7/26
NervGen Pharma successfully raised US$60 million through a public offering
8/7/26
NervGen announces $10M private placement for anticipated Nasdaq listing with SCI Ventures' support
21/11/25
Major BCI firm Precision Neuroscience inks partnership with SCI Ventures
29/8/25
"Superman" backed Fund partners with Healx AI to fight Paralysis
31/3/25
EG 427 is dosing first SCI patient in clinical trial for neurogenic bladder
31/3/25
SCI Ventures backs EG 427 for clinical trial in SCI bladder dysfunction
28/8/24
Managing Partner Adrien Cohen on French National Business TV BFM about SCI Ventures
28/8/24
Why five spinal cord injury organizations teamed up to launch a new venture philanthropy fund
21/11/25
SCI Ventures Launches Venture Philanthropy Fund to Accelerate Restorative Treatments for Spinal Cord Injury and a Cure for Paralysis
10/6/24
Charities create fund to invest in spinal cord injury companies
15/5/24
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting
16/5/24
Augmental wins Best Pitch at CES 2024
10/6/24
Musk touts Neuralink's first patient as a big step. Experts say it's part of long legacy.
Portfolio

Explore our latest investments

NervGen Pharma

Precision Neuroscience

Healx

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
DenyAccept